Search

In order to improve poor mechanical properties and easy corrosion of superhydrophobic coatings, one performance organofluoroacrylic resin/SiO2 superhydrophobic coating was prepared by spraying method with organofluoroacrylic resin and 1H, 1H, 2H, 2H-perfluorodecyltrimethoxysilane modified nano-SiO2 as raw materials. The influence of nano-SiO2 modification conditions was discussed on the wet ability of modified nano-SiO2, and the drag reduction performance, anti-corrosion performance and wear resistance of the coating were evaluated by pipeline resistance experiment, electrochemical workstation and friction experiment. The results show that the surface of the organofluoroacrylic resin/SiO2 superhydrophobic coating has a multi-stage rough structure with good superhydrophobic properties, and the contact angle of the superhydrophobic coating sprayed on the stainless steel and aluminum alloy substrates is slightly smaller than that of the glass substrate. The surface of the coating has the slipping under a certain flow rate, and the drag reduction rate of the superhydrophobic coating with a ratio of 1∶1 is high, reaching 24.54%. At the same time, through the polarization curve and AC impedance analysis, the current density of the dimensional passivity decreases greatly, which has a good anti-corrosion protection effect on stainless steel, and the coating has good corrosion resistance. In addition, the coating has relatively good wear resistance on stainless steel and aluminum alloy substrates, and is still superhydrophobic after 12 cycles of friction.

Background: There is a lack of actual and comprehensive data on the detection rate of neuronal surface antibodies in patients with unexplained epilepsy in China. Thus, we attempted to analyze the differences in clinical manifestations, cerebrospinal fluid (CSF) characteristics, seizure types and other aspects of antibody-positive and negative patients, to identify suspected antibody-positive epilepsy patients. Methods: In total, 137 inpatients with unexplained epilepsy were consecutively included, and neuronal surface antibodies (NSAbs) were detected by serological and/or CSF evaluations. The clinical features and seizure characteristics were analyzed between the NSAb-positive and negative patients. In addition, patients were divided into four groups based on CSF and blood antibody titers. CSF cell count and protein content were analyzed in relation to antibody titers. Results: There were 45 (32.8%) patients tested positive for antibodies. Multivariate analyses revealed that age, mental status changes or memory deterioration, CSF protein, CSF cell count, treatment, days of hospitalization, outcome, duration of symptoms before hospitalization, status epilepticus, and number of antiepileptic drugs were significantly associated with the NSAb-positive group and changes in inflammatory indicators in routine CSF analysis were associated with antibody titers. Conclusions: A relatively high proportion of patients with unexplained epilepsy have positive NSAbs. Patients with the above clinical characteristics need to be highly suspected of NSAbs positivity and should be tested for antibodies in time to assist treatment. The decrease of CSF cell count and protein content has suggestive value for the decrease of antibody titer, which should be evaluated in the follow-up. [ABSTRACT FROM AUTHOR]